March 27, 2024, Akebia received FDA approval of Vafseo(vadadustat) tablets for the treatment of anemia due to chronic kidney disease (CKD) in adult patients on dialysis.
Vafseo(vadadustat) tablets is a once-daily oral hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor that activates the physiologic response to hypoxia to stimulate endogenous production of erythropoietin, increasing hemoglobin and red blood cell production to manage anemia.